Conference abstractPublished 26 Jul 2017
The integrated 152 solid tumor panel for early-line and advanced stage treatment decisions in solid tumors
Integrated Molecular Diagnostics Pathology, Inc., USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Comprehensive genetic profiling of tumors using next generation sequencing (NGS) is gaining acceptance for guiding treatment decisions in cancer care. We designed a cancer profiling test that integrates results from NGS with more traditional results obtained by immunohistochemistry (IHC) of solid tumor tissues. Relevant regions of genes known to be implicated in solid tumors are targeted for deep sequencing. The tight concordance between some somatic mutations and the standard-ofcare (SOC) therapeutics administered in clinical practice makes identification of such mutations in a specific tumor invaluable in guiding personalized and rational treatment of the patient. The SOC report is provided in a short turnaround time for four tumors, namely lung, breast, colon and melanoma, followed by a full report that includes drug candidates available through clinical trials. For all other tumor types, a full report is provided. Our Integrated 152 solid tumor panel not only detects single nucleotide polymorphisms (SNPs), but will identify copy number variations (CNVs) and some translocations in 152 cancer-related genes. We describe the standardization, validation, and clinical utility of the Integrated 152 Solid tumor test on approximately 250 solid tumor formalin-fixed paraffin-embedded (FFPE) disease samples and control cell-line samples. These studies showed high reproducibility and accuracy (~99%). When therapeutics in clinical trials was included, clinically relevant recommendations increased to 95% for patients in advanced stages of cancer. We present data to demonstrate how the Integrated 152 Solid Tumor Test may be used in clinical practices.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pathology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Melanie Yong”